Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors
The FEBS Journal · 2025
DOI: 10.1111/febs.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Maria Teresa Borrello und 25 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle Fibrosis Research Group, Bioscience Institute, Faculty of Medical Sciences, Newcastle University, UK. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Liver Cirrhosis, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia, National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC), Rosetrees Trust.
Abstract (Originalsprache)
Chronic liver injury characterized by unresolved hepatitis leads to fibrosis, potentially progressing to cirrhosis and hepatocellular carcinoma. Effective treatments for halting or reversing liver fibrosis are currently lacking. This study investigates the potential of HDAC6 as a therapeutic target in liver fibrosis. We synthesized two selective HDAC6 inhibitors, DR‐3 and FDR2, and assessed their effects on hepatic stellate cell (HSC) activation and liver fibrosis using human precision cut liver slices (hPCLS). Molecular docking, deacetylation inhibition assays, and various cellular assays were employed to evaluate the specificity and anti‐fibrotic efficacy of these inhibitors. DR‐3 and FDR2 demonstrated high selectivity for HDAC6 over HDAC1, significantly inhibiting HSC activation markers and fibrogenic gene expression. Both inhibitors increased acetylation of α‐tubulin and suppressed TGF‐β1‐induced SMAD signaling in HSCs. In human precision cut liver slices (hPCLS), DR‐3 and FDR2 reduced fibrogenic protein levels and collagen deposition. The selective inhibition of HDAC6 by DR‐3 and FDR2 effectively reduces HSC activation and fibrogenesis in liver models, supporting further investigation of HDAC6 inhibitors as potential anti‐fibrotic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newcastle Fibrosis Research Group, Bioscience Institute, Faculty of Medical Sciences, Newcastle University, UK.
- School of Pharmacy and Pharmaceutics, Faculty of Health Sciences and Wellbeing, University of Sunderland, UK.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Serbia.
- Bioimaging Unit, Faculty of Medical Sciences, Newcastle University, UK.
- FibroFind, Newcastle upon Tyne, UK.
- Department of Hepatobiliary Surgery, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
ORCID-Profile: Jelena Mann
Förderung
- Ministry of Science, Technological Development and Innovation, Republic of Serbia
- National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC)
- Rosetrees Trust
- EU Regional Development Fund
- Cancer Research UK
- Medical Research Council
- National Institute for Health and Care Research
Zitieren
APA
Borrello, M. T., Ruzic, D., Paish, H., Graham, E., Collins, A. L., Scott, R., Higginbotham, S., Radovic, B., Nelson, G., Bulmer, D., Borthwick, L. A., Robinson, S. M., French, J., Moir, J., White, S. A., Wilson, C., Pandanaboyana, S., Hammond, J., Thakkar, R., …, & Mann, J. (2025). Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors. The FEBS Journal. https://doi.org/10.1111/febs.70062
Vancouver
Borrello MT, Ruzic D, Paish H, Graham E, Collins AL, Scott R, et al. Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors. The FEBS Journal. 2025. doi:10.1111/febs.70062
BibTeX
@article{Borrello2025,
author = {Borrello, Maria Teresa and Ruzic, Dusan and Paish, Hannah and Graham, Eleanor and Collins, Amy L and Scott, Rebecca and Higginbotham, Sam and Radovic, Branko and Nelson, Glyn and Bulmer, David and Borthwick, Lee A and Robinson, Stuart M and French, Jeremy and Moir, John and White, Steve A and Wilson, Colin and Pandanaboyana, Sanjay and Hammond, John and Thakkar, Rohan and Alrawashdeh, Wasfi and Figueiredo, Rodrigo and Petkovic, Milos and Nikolic, Katarina and Oakley, Fiona and Mann, Derek A and Mann, Jelena},
title = {Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70062}
}
EUVIMED